Previous close | 26.32 |
Open | 26.06 |
Bid | 25.95 x 100 |
Ask | 26.03 x 200 |
Day's range | 25.57 - 26.88 |
52-week range | 17.52 - 43.81 |
Volume | |
Avg. volume | 483,438 |
Market cap | 699.257M |
Beta (5Y monthly) | 2.60 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.12 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 67.63 |
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a biotechnology company focused on the discovery, development, and commercialization of RNA therapeutics for rare diseases and vaccines, has reported an insider transaction.
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a biotechnology company focused on the discovery, development, and commercialization of RNA therapeutics for rare diseases and vaccines, has reported an insider sale according to a recent SEC filing.
Arcturus Therapeutics Holdings ( NASDAQ:ARCT ) Full Year 2023 Results Key Financial Results Revenue: US$166.8m (down...